Search
Research
Systematic review and meta-analysis of respiratory viral coinfections in childrenCoinfection is not associated with increased clinical severity, but further investigations by pathogen pairs are warranted
Research
Optimization is required when using linked hospital and laboratory data to investigate respiratory infectionsChart review to validate linked microbiological data
Research
Morbidity due to acute lower respiratory infection in children with birth defects: A total population-based linked data studyChildren with birth defects experience higher rates of hospitalisation for ALRIs before age 2 years than children with no birth defects.
Research
Spatiotemporal patterns of drug susceptible and drug resistant tuberculosis in Hunan Province, ChinaInvestigators: Kefyalew Alene, Archie Clements External collaborators: Kerri Viney, Dr Darren J Gray (Australian National University) Zuhui Xu (
This tool is designed to help current and future parents and caregivers as well as health care providers. It is currently based on the 2025 Western Australian RSV immunisation program.
Research
How Accurate Are International Classification of Diseases-10 Diagnosis Codes in Detecting Influenza and Pertussis Hospitalizations in Children?Influenza diagnosis codes had high specificity (98.6%) and modest positive predictive value (PPV; 84.1%) and sensitivity (86.1%) for a laboratory-confirmed...
Research
Hospitalisation for bronchiolitis in infants is more common after elective caesarean deliveryThe authors previously reported an increased risk of hospitalisation for acute lower respiratory infection up to age 2 years in children delivered by...
Research
Influenza vaccine effectiveness against laboratory-confirmed influenza in healthy children aged 6-59 months:The Western Australian Influenza Vaccine Effectiveness study commenced in 2008 to evaluate a new program to provide free influenza vaccine to all children...
Research
Assessing the protective effect of influenza vaccine against laboratory confirmed influenza in hospitalised children aged 6-59 monthsInfluenza vaccine was offered to all children aged 6-59 months resident in Western Australia in 2008, and we wished to evaluate the effectiveness of this immunisation programme.
Research
Respiratory Syncytial Virus Strain Evolution and Mutations in Western Australia in the Context of Nirsevimab ProphylaxisNirsevimab is a long-acting monoclonal antibody used to prevent respiratory syncytial virus (RSV) infection in infants and high-risk children. During the 2024 RSV season in Western Australia, 21 922 doses were administered to infants entering their first season and 1221 doses to at-risk children. In this context, the selection and spread of escape variants are a potential concern. This study aimed to investigate nirsevimab binding site mutations using clinical and wastewater data.